Skip to main content
. 2019 May 23;4(3):e000491. doi: 10.1136/esmoopen-2019-000491

Figure 2.

Figure 2

Differences in adverse event frequencies: combination therapies versus vemurafenib monotherapy. CPK, creatine phosphokinase; cSCC, cutaneous squamous cell carcinoma; PPH, palmoplantar hyperkeratosis.